Association of Women’s Health, Obstetric, & Neonatal Nurses (AWHONN) encourages an exclusive human milk diet (EHMD) for vulnerable preterm infants in the neonatal intensive care unit (NICU)
Type: Press Releases
Topic(s): Advocacy Bronchopulmonary Dysplasia (BPD) Feeding Intolerance Late-Onset Sepsis Mortality Necrotizing Entercolitis (NEC) Retinopathy of Prematurity (ROP)
Prolacta Bioscience hosts panel session on the need for uniform human milk safety standards at 2021 National Coalition for Infant Health Summit
Type: Press Releases
Topic(s): Advocacy Company Quality & Safety
Prolacta Bioscience supports Breastfeeding Awareness Month with donation of breast pumps to Alliance for Black NICU Families
Type: Press Releases
Topic(s): Company Parents
Prolacta Bioscience congratulates Carolyn TenEyck, RN, on lifetime achievement award from National Black Nurses Association
Type: Press Releases
Topic(s): Advocacy Legislative
Enrollment completed in clinical trial evaluating effect of exclusive human milk diet including a specialty fortifier in term infants born with single ventricle physiology
Type: Press Releases
Topic(s): Single Ventricle Congenital Heart Defects (SVP )
Four studies showed Prolacta Bioscience’s 100% human milk-based fortifiers reduced retinopathy of prematurity (ROP) in premature infants
Type: Press Releases
Topic(s): Retinopathy of Prematurity (ROP)
Prolacta Bioscience provides update on latest SARS-CoV-2 data and continued safety of its human milk-based nutritional products
Type: Press Releases
Topic(s): Quality & Safety
Late-onset sepsis reduced in premature infants fed Prolacta’s 100% human milk-based fortifiers as part of an exclusive human milk diet
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Late-Onset Sepsis
Prolacta Bioscience fortifiers reduce risk of serious lung disease and hospital costs among premature infants, compared to cow milk-based fortifiers
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD)
